🇺🇸 FDA

Drug profile · INN

lotilaner

XDEMVY

approved
US status
approved
Patents linked
3
News articles
0

Quick answer

lotilaner (XDEMVY) is an FDA-listed pharmaceutical active ingredient. Associated with Tarsus Pharmaceuticals. Route of administration: ophthalmic. Current US regulatory status: approved.

Key facts

INN lotilaner
Brand XDEMVY
Route OPHTHALMIC
Formulation SOLUTION/DROPS
Originator Tarsus Pharmaceuticals

Related patents

Search patents →

  1. US 11752137

    Ophthalmic compositions for treating ocular Demodex using lotilaner formulations

    Expires Mon Sep 07 2043 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  2. US 11690826

    Methods for treating demodex blepharitis using lotilaner formulations

    Expires Mon Jun 29 2043 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  3. US 11690827

    Methods for treating ocular Demodex using lotilaner formulations

    Expires Mon Jun 29 2043 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

Frequently asked questions

What is lotilaner?

lotilaner (XDEMVY) is an FDA-listed pharmaceutical active ingredient. Associated with Tarsus Pharmaceuticals. Route of administration: ophthalmic. Current US regulatory status: approved.

What is the brand name for lotilaner?

XDEMVY is a marketed brand name for lotilaner. Check FDA Drugs@FDA for the current US label holder and prescribing information.

What is the US approval status of lotilaner?

lotilaner has approved status in the United States according to our Drugs@FDA-derived records. Verify on the official FDA label before clinical or commercial decisions.